Your session is about to expire
← Back to Search
WP1302 400μg for Graves Disease
Study Summary
This trial is testing the withdrawal of Methimazole in people with Graves' disease. Participants will go through different periods, including screening, treatment with Methimazole or placebo, tapering off Methim
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the inclusion criteria for this research study open to individuals below 25 years of age?
"Enrollment is restricted to individuals over 18 years old but under the age of 65."
Who is eligible to participate in this clinical study?
"Individuals diagnosed with Graves' disease aged between 18 and 65 are eligible for enrollment in this clinical trial, which has a capacity of admitting 176 participants."
Are researchers currently enrolling participants for this medical study?
"Per clinicaltrials.gov, this investigation is actively seeking participants. Initial posting of the trial was on January 11th, 2024 and it underwent its latest update on January 25th, 2024."
How large is the overall participant pool in this medical study?
"Indeed, the details on clinicaltrials.gov highlight that this investigation is actively seeking participants. The trial was initially published on January 11th, 2024 and last revised on January 25th, 2024. Enrollment of a total of 176 patients is planned at one designated site."
Has the drug WP1302 400μg been granted approval by the FDA?
"Based on our evaluation at Power, the safety rating for WP1302 400μg is set at 2 due to its Phase 2 trial status. This suggests some evidence backing its safety profile but lacking data supporting efficacy."
Share this study with friends
Copy Link
Messenger